Characterization of thrombosis risk in ambulatory patients with cancer

Background: Venous thromboembolism (VTE) is one of the leading causes of death in patients with cancer. Currently, there is a need to develop an easily applicable risk model that can identify patients who will benefit from receiving primary thromboprophylaxis to reduce the incidence of VTE. Patients...

Descripción completa

Detalles Bibliográficos
Autores: Trujillo-Santos, Javier|||0000-0003-0861-9927, García-Escobar, Ignacio|||0000-0002-1068-0455, Salgado, Mercedes, Araújo, António|||0000-0002-7267-3584, Martínez de Castro, Eva|||0000-0002-5772-0741, Molina, Raquel, Castellón-Rubio, Victoria E.|||0000-0001-8817-2912, Domènech, Pere, Gallardo Díaz, Enrique|||0000-0002-1375-3488, Colomé, Esteve|||0000-0001-6478-2708, Torres, Ferran|||0000-0002-7355-7913, Benítez Montañez, José Carlos, Porta, Rut|||0000-0001-6179-9563, Lobo de Mena, Miriam|||0000-0002-8249-7721, Malheiro, Mariana|||0000-0001-6200-6959, Font, C.|||0000-0002-3547-7373, Brozos-Vázquez, Elena|||0000-0003-4958-4142, Garicano, Fernando, Sapena, Victor|||0000-0003-4379-6486, Costa, Ana-Lucia, Albuquerque, Ana Cristina, Cerezuela, Pablo
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:326607
Acceso en línea:https://ddd.uab.cat/record/326607
https://dx.doi.org/urn:doi:10.1093/oncolo/oyae334
Access Level:acceso abierto
Palabra clave:D-dimer
Leukocytes
Thromboprophylaxis
Venous thromboembolism
Cancer
Descripción
Sumario:Background: Venous thromboembolism (VTE) is one of the leading causes of death in patients with cancer. Currently, there is a need to develop an easily applicable risk model that can identify patients who will benefit from receiving primary thromboprophylaxis to reduce the incidence of VTE. Patients and methods: This was a non-interventional, multicenter, observational, prospective study carried out in 62 Oncology and Hematology services in Spain and Portugal between January 2018 and December 2019. The main objective of the CARTAGO study was to develop a predictive model within a competitive risk framework to assess the risk of VTE in patients with cancer undergoing chemotherapy, biological, or hormonal treatment. Results: A total of 1596 patients were analyzed. VTE events occurred in 124 (8%) during the 6-month follow-up period (42% of deep vein thrombosis [DVT], 48% of pulmonary embolism [PE], and 10% of both DVT and PE). Four variables were selected for the multivariate predictive model to determine the risk of VTE (tumor type, D-dimer, compression of a vessel by the tumor, and leukocyte count). The 4 variables were associated with an increased risk of VTE (C-statistic, 0.646 [95%CI, 0.620-0.673]). The most significant variables in the internal validation with bootstrapping were the "very high risk"tumors (hazard ratio [HR] 2.032; 95%CI, 1.287-3.211). Conclusion: The CARTAGO model predicts the VTE risk in patients with cancer receiving anticancer therapy in an outpatient setting. This model can easily aid in identifying ambulatory patients who would probably benefit from primary thromboprophylaxis.

Similares en LA Referencia